Your search history is turned on.
Date: May 2, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Discusses Filing of Financial Statements Toronto, Ontario--(Newsfile Corp. - May 2, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), announces that, it intends to file its audited ...
Date: April 17, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Announces Closing of Tranche of Private Placement Toronto, Ontario--(Newsfile Corp. - April 17, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder (AUD), is pleased to announce that, further...
Date: April 3, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Announces Launch of Licensing Partnership Agreement with Oklahoma Based Clinic Awakn also announces Private Placement Toronto, Ontario--(Newsfile Corp. - April 3, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus ...
Date: February 12, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Announces Listing on the Canadian Securities Exchange Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that it has receive...
Date: February 8, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Form 51-102F3 - Material Change Report - Tranche 5 FORM 51-102F3 MATERIAL CHANGE REPORT 1. Name and Address of Company Awakn Life Sciences Corp. 217 Queen W, Suite 301 Toronto, ON M5V 0R2 2. Date of Material Change February 8, 2024 3. News Release A press release disclosing the material change was r...
Date: February 5, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Announces Conditional Approval of CSE Listing Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-stage biotechnology company developing medication-assisted treatments for addiction with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce, further to its press releas...
Date: January 24, 2024 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Completes Successful Investigative Study to Establish Dissociative Effect of a Proprietary Sublingual S-Ketamine Oral Thin Film Formulation in Harmful Drinkers Awakn Designates Program AWKN-002 for Alcohol Use Disorders in the US Market Toronto, Ontario--(Newsfile Corp. - January 24, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a clinical-...
Date: December 20, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Enters Global Licensing Agreement For Proprietary Sublingual S- Ketamine Formulation With LTS Agreement Includes Exclusive Rights for Treatment of Addiction, Anxiety and Eating Disorders Also Includes Access to Phase 1 Data and Patents Filed in US and Key International Markets Toronto, Ontario--(Newsfile Corp. - December 20, 2023) - Awakn Life Sciences Corp. (NEO: AWKN...
Date: December 15, 2023 Jurisdictions: Alberta, British Columbia, Ontario
Awakn Life Sciences Provides Corporate Update Toronto, Ontario--(Newsfile Corp. - December 15, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (Awakn), a clinical-stage biotechnology company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), shares a corporate update on recent progress. Awakn also announces the closing of the ...
Date: December 14, 2023 Jurisdictions: Alberta, British Columbia, Ontario
1 Form 52-109F2 Certification of Interim Filings Full Certificate I, Jonathan Held, CFO of Awakn Life Sciences Corp., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the interim filings) of Awakn Life Sciences Corp. (the issuer) for the interim period ended October 31, 2023. 2. No mi...